RxDoctor Payments Data

Daniel Curhan, MD

Urology · Santa Barbara, CANPI 1760491112

Payments from drug & device makers

$14,932in general payments, 2019–2025

Across 168 payments — averaging $88.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$7K
  • Boston Scientific$1K
  • Teleflex LLC$712
  • Coloplast$574
  • Valencia Technologies Corporation$553
  • Procept Biorobotics Corporation$369
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$5,89639%
  • Travel & lodging$1,80712%
  • Food & beverage$7,21148%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,932 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$342,119
Medicare patients
873
Services billed
7,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron116$113,740
MyrbetriqMirabegron107$88,158
Finasteride825$12,384
Dutasteride163$7,864
PremarinEstrogens, Conjugated14$6,376
Tamsulosin Hcl427$6,123
Silodosin64$5,773
Estradiol15$3,462
Potassium Citrate ErPotassium Citrate29$2,969
Methenamine Hippurate20$2,005
Alfuzosin Hcl ErAlfuzosin Hcl46$1,318
Tadalafil11$502
Oxybutynin Chloride ErOxybutynin Chloride14$444
Doxazosin Mesylate16$313
Ciprofloxacin Hcl53$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$124$113,740116 claims
Astellas Pharma US IncMyrbetriq$7,447$88,158107 claims
PfizerPremarin$211$6,37614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.

Other urology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →